A polymorphism in the dysbindin gene (DTNBP1) associated with multiple psychiatric disorders including schizophrenia
© Voisey et al; licensee BioMed Central Ltd. 2010
Received: 12 April 2010
Accepted: 9 July 2010
Published: 9 July 2010
A number of studies have found associations between dysbindin (DTNBP1) polymorphisms and schizophrenia. Recently we identified a DTNBP1 SNP (rs9370822) that is strongly associated with schizophrenia. Individuals diagnosed with schizophrenia were nearly three times as likely to carry the CC genotype compared to the AA genotype.
To investigate the importance of this SNP in the function of DTNBP1, a number of psychiatric conditions including addictive behaviours and anxiety disorders were analysed for association with rs9370822.
The DTNBP1 polymorphism was significantly associated with post-traumatic stress disorder (PTSD) as well as nicotine and opiate dependence but not alcohol dependence. Individuals suffering PTSD were more than three times as likely to carry the CC genotype compared to the AA genotype. Individuals with nicotine or opiate dependence were more than twice as likely to carry the CC genotype compared to the AA genotype.
This study provides further support for the importance of DTNBP1 in psychiatric conditions and suggests that there is a common underlying molecular defect involving DTNBP1 that contributes to the development of several anxiety and addictive disorders that are generally recognised as separate clinical conditions. These disorders may actually be different expressions of a single metabolic pathway perturbation. As our participant numbers are limited our observations should be viewed with caution until they are independently replicated.
Dystrobrevin binding protein 1 (DTNBP1) is a neuronal protein that binds to alpha- and beta-dystrobrevin in muscle and brain . Association and functional studies suggest a role for the DTNBP1 gene in schizophrenia. Linkage studies first identified DTNBP1 as a region of high schizophrenia susceptibility [2–4] and polymorphisms in DTNBP1 have since been identified to be associated with schizophrenia [3, 5, 6]. Biologically, DTNBP1 is a strong candidate for schizophrenia pathogenesis as it is thought to play a pivotal role in regulating the glutamatergic system [7, 8]. Glutamate hypofunction leads to increased sensory flooding and changes in dopamine concentration. Hence, glutamate receptor agonist drugs are now used in the treatment of schizophrenia . Functional studies of DTNBP1 provide further evidence for its role in schizophrenia aetiology. Reduced DTNBP1 mRNA expression in cerebral cortex has been associated with risk haplotypes for schizophrenia . Reduced DTNBP1 mRNA and protein expression has been found in the hippocampal formation and dorsolateral prefrontal cortex of schizophrenia patients [11–13]. Schizophrenia patients showed reduced presynaptic DTNBP1 which was related to glutamatergic alterations in intrinsic hippocampal formation connections . More recently, it has been established that reductions in protein in the brains of schizophrenia patients occurred in the dysbindin-1C isoform but not dysbindin-1A or -1B . Studies also concluded that dysbindin-1C in the human brain is concentrated in the synapses . Tang et al.  concluded that decreased dysbindin-1C in the dorsolateral prefrontal cortex may induce NMDA receptor hypofunction in fast-spiking interneurons contributing to the cognitive deficits of schizophrenia.
DTNBP1 is associated with other psychotic conditions. Association with DTNBP1 was found with bipolar disorder but only in a small subgroup characterised by the complication of psychotic features during episodes of mood disturbance . Methamphetamine psychosis is clinically similar to schizophrenia [16, 17] and a recent study hypothesised that DTNBP1 may also be associated with substance-induced psychoses . Significant associations with methamphetamine psychosis and DTNBP1 variation was identified in a case-control study .
The aim of this study was to examine whether DTNBP1 variation shows genetic association with a range of psychiatric conditions, including schizophrenia, suggesting that changes in metabolism related to variations in DTNBP1 protein function underlies a common molecular defect in these conditions. A polymorphism in the human dopamine D2 receptor (DRD2) (rs6277) has previously been found to be associated with a number of psychiatric conditions or traits associated with psychopathology. The DRD2 polymorphism was first found to be associated with schizophrenia . Since this study rs6277 has also been found to be associated with post-traumatic stress disorder (PTSD) , working memory ability , impulsivity  and alcohol dependence . Like the DRD2 polymorphism, a common polymorphism in DTNBP1 may be associated with a range of psychiatric conditions. In a previous study, we found a polymorphism in DTNBP1 (rs9370822) that was strongly associated with schizophrenia . It is also well known that anxiety and addictive disorders are common comorbidities of schizophrenia [25, 26], so, to examine the importance of this DTNBP1 SNP in addictive and anxiety disorders, a number of psychiatric groups were genotyped for rs9370822.
The control group consisted of 250 unrelated Caucasians (102 female and 148 male) with a mean age of 36.8 years (s.d. ± 12.8 years). The control group consisted mostly of medical and nursing staff recruited through hospitals, and university students and academic staff. Formal screening for psychological disorders was not undertaken in the control population. As such the controls represent an unselected control group.
A total of 120 unrelated Caucasian participants (50 female and 70 male) diagnosed as opiate dependent were recruited for this study, all of whom were being assessed for naltrexone treatment as outpatients of the Hospital Alcohol and Drug Services Unit of the Royal Brisbane and Women's Hospital. Participants had a mean age of 28.7 years of age. Approximately half of the participants were being managed on methadone prior to detoxification (47.2%) while the other half were on heroin (52.8%). Those on methadone had a mean dose of 48.1 milligrams (s.d. 30.5), with a range between 10-165 milligrams. The mean age of onset of heroin use was 22.4 years of age (s.d. 5.14), with a range between 15-43 years. Mean number of participant-reported detoxifications prior to this occasion was 3.5 (s.d. 3.3), with a range between 0-16 detoxifications. Cannabis was the most commonly concurrently used illicit substance reported by participants prior to treatment (52.5% reported use), followed by amphetamines (14.9% reported use).
A total of 127 unrelated male Caucasian patients diagnosed with PTSD using Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria were recruited through the Greenslopes Private Hospital for the study. All subjects were Vietnam combat veterans who had served in the Australian Armed Forces with a mean age of 52.3 years (s.d. ± 6.1 years). None were being treated with psychotropic medications. Patients were excluded from the study if they had a diagnosis of psychosis, bipolar disorder, obsessive-compulsive disorder, or organic brain syndrome including dementia. All subjects had sufficient comprehension of English and could understand the administered questionnaires. Patients were assessed for PTSD by a consultant psychiatrist or a senior psychiatric registrar using DSM-IV criteria. Furthermore, every patient exceeded the clinical cut-off score of 94 on the Mississippi Scale for combat-related PTSD . Patient clinical history and demographic data including ethnic background were also obtained. After the procedure had been fully explained, all participants provided written informed consent. They were able to terminate their involvement at any time during the interview without prejudice. Institutional ethics approval was obtained from the Greenslopes Private Hospital.
A total of 231 unrelated Caucasian (47 female and 184 male) alcohol dependent subjects were recruited from large public hospitals in Brisbane, Australia. The mean age of the group was 42.1 years (s.d. ± 10.8 years). All subjects were assessed by a clinical psychologist experienced in drug and alcohol dependence and met DSM-IV criteria of alcohol dependence disorder. All were inpatients and represented a spectrum of severity with a significant proportion (n = 65) of these patients being diagnosed with two or more alcohol related medical conditions such as pancreatitis, cirrhosis, hepatitis or peripheral neuropathy. Alcohol dependent patients were excluded from the study if they had dementia, delirium, psychosis, or any other condition that would affect their ability to provide informed consent.
A total of 147 (68 male, 79 female) unrelated Caucasians with a mean age of 43.3 (s.d. ± 11.1 years) were recruited for this study through hospital and media advertisements. Participants were 18 years of age or older and had smoked for at least three years and were generally healthy despite currently smoking 15 cigarettes or more per day. All were motivated to reduce smoking and had the goal of eventual cessation. However, all participants had at least one serious but unsuccessful attempt at quitting in the previous 24 months. One hundred and thirty nine of the participants were administered the Fagerstrom test for nicotine dependence .
To minimise population stratification bias, both control and clinical subjects were recruited in the Brisbane region (a city of approximately 2 million inhabitants on the East Coast of Australia) and all were of British or European descent.
Ethics approval was obtained from all institutions involved and each participant gave written informed consent. This study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).
Oragene kits were used to extract DNA from saliva samples. Samples were genotyped using a homogeneous MassEXTEND (hME) Sequenom assay performed by the Australian Genome Research Facility. The hME assay is based on the annealing of an oligonucleotide primer (hME primer) adjacent to the SNP of interest. The addition of a DNA polymerase along with a mixture of terminator nucleotides allows extension of the hME primer through the polymorphic site and generates allele-specific extension products, each having a unique molecular mass. The resultant masses of the extension products are then analysed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and a genotype is assigned in real time. The hME assay was performed in multiplex with up to 36 reactions in a single well. Genotyping failure rates varied between two and five percent in the different groups.
A Pearson's χ2 test was performed to identify statistical associations between alleles and genotype and schizophrenia status. Odds ratios (OR) were also calculated. Tests were performed on both genotype and allele data. Statistical tests were performed using the COMPARE2 program from the WinPepi suite of epidemiology programs  and SPSS version 16. Hardy-Weinberg equilibrium (HWE) was computed using Utility Programs for Analysis of Genetic Linkage . The analysis of genotypes under a recessive model involved pooling the low-risk homozygotes and the heterozygotes and comparing frequencies with the high-risk homozygotes, i.e. OR > 1. Data were not corrected for multiple testing as only one SNP was tested in five entirely separate case groups.
Allele association of DTNBP1 SNP rs9370822
Genotype association of DTNBP1 SNP rs9370822
Examination of the genotype odds ratios suggests that, like PTSD, a partially dominant mode of inheritance is operating for nicotine dependence. However, when compared to the low-risk homozygote, the odds ratio of the other two genotypes indicated that either a very weak partially dominant mode of inheritance or, more likely, a C-allele-recessive pattern of inheritance for schizophrenia and opiate dependence was present, i.e. both the heterozygote OR and the OR for the low-risk homozygote were approximately one. The rs9370822 SNP was found to be associated with schizophrenia and opiate dependence when analysed under a recessive model by pooling genotypes (schizophrenia recessive pattern of inheritance, p = 0.0017, OR = 2.51 95% CI 1.34 to 4.74; opiate dependence recessive pattern of inheritance, p = 0.014, OR = 2.22 95% CI 1.10 to 4.46).
Alcohol dependence was not found to be associated with rs9370822 at the genotype level or under any inheritance model. All sample groups were determined to be in Hardy-Weinberg equilibrium based on the respective genotype frequencies of each group (controls, χ2 = 0.007, p = 0.93; PTSD, χ2 = 0.272, p = 0.60; opiate dependence, χ2 = 2.11, p = 0.15; nicotine dependence, χ2 = 0.64, p = 0.42; alcohol dependence, χ2 = 0.12, p = 0.73).
In order to identify a common molecular mechanism of disease etiology, DTNBP1 SNP, rs9370822, was chosen for analysis in a number of psychiatric conditions as we found it to be significantly associated with schizophrenia in a previous study . To replicate our findings and examine the importance of this SNP in psychiatric disorders and potential brain functioning, we analysed a number of groups including addictive behaviours and anxiety disorders. In addition to schizophrenia, analysis of rs9370822 revealed associations with PTSD, opiate dependence and nicotine dependence at both the allele and genotype levels. Alcohol dependence was not found to be associated with rs9370822 in our study but association with rs9370822 cannot be ruled out as we only analysed 231 alcohol dependent cases and the p-value was approaching significance at both the allele and genotype level (Tables 1 and 2). While a strong effect of DTNBP1 was observed in four clinically distinct phenotypes the results should be treated with caution as there is a considerable difference in the gender proportions between cases and controls, for example the PTSD cohort were all male while 41% of controls were women. Also, because five different diseases were examined it is not surprising that there are also differences with regard to age (ranging from a mean age of 29 years in opiate dependent cases to 52 years in Vietnam veterans with PTSD).
Our schizophrenia study was the first to identify rs9370822 to be associated with a psychiatric condition . The position of this SNP is likely to be a region for high schizophrenia susceptibility as three other SNPs (rs875462, rs760666 and rs7758659) flank rs9370822 and have been found to be significantly associated with schizophrenia [5, 31]. We also found two other flanking SNPs (rs9370823 and rs4236176) to be associated with schizophrenia in a recent study . Although the rs9370822 SNP is intronic it is possible that it is a functional SNP that affects RNA splicing or gene transcription. It could also be in linkage disequilibrium with a functional SNP. However a functional polymorphism in a nearby region that is associated with any psychiatric condition has yet to be identified.
The relationship between abnormal dysbindin function and addictive and anxiety disorders is unclear. Our findings may indicate that the rs9370822 polymorphism affects susceptibility to addictive and anxiety disorders by implication of glutamatergic neurotransmission or the dopamine system. We previously identified rs9370822 to follow a recessive pattern of inheritance with respect to schizophrenia risk  which is consistent with the recessive inheritance of dysbindin-1 gene deletion in the mouse model of schizophrenia . In this study we also observed that opiate dependence appeared to follow a recessive pattern of inheritance. However, PTSD and nicotine dependence appeared to follow a partially dominant pattern. Given this, it is possible that rs9370822 results in a reduction of DTNBP1 function resulting in a recessive loss-of-function pattern in certain disorders, presumably because the loss of function from one allele is not sufficient to increase susceptibility to disease detectably but loss of function of both alleles does. In other disorders a haploinsufficiency mechanism is operating and results in a partially dominant mode of inheritance, i.e. loss of function in one allele increases susceptibility to disease but not as much as loss of function in both alleles.
It has also been reported that variation in DTNBP1 may affect the dopamine pathway as dysbindin overexpression decreases dopamine release and suppression of dysbindin expression increases dopamine release in the mouse in vitro. A study has also found that dysbindin deficiency can increase the level of cell surface DRD2 and enhance DRD2 signalling .
The DTNBP1 polymorphism identified in this study is possibly involved in psychiatric liability not only for schizophrenia but also for addictive and anxiety disorders. It is possible that DTNBP1 variation affects a common pathway involved in anxiety and addictive disorders. Whether this pathway involves dopamine or glutamate signalling or both, remains to be elucidated. As our participant numbers are limited our observations should be viewed with caution until they are independently replicated. However, the associations are unlikely to occur by chance due to sample size as five separate groups were analysed (including schizophrenia in a previous study) and four have been found to be significantly associated with rs9370822. Although this SNP is intronic, it has been found to be strongly associated with schizophrenia, PTSD, opiate and nicotine dependence. Future studies may explore whether this SNP is functional and what effect it has on DTNBP1 functioning in the brain.
Our findings are at odds with current knowledge as these conditions are generally regarded as separate clinical entities. However, our data suggests that these conditions may be different phenotypic expressions of the same fundamental molecular defect in either the dopamine or glutamate pathways, or both. Supporting this idea, a recent review of genome-wide association studies in schizophrenia  suggested that a pleiotropic mechanism may underlie the genetic overlap of schizophrenia with autism and with bipolar disorder.
Funding for this study was provided by the Queensland State Government, the Nicol Foundation and the Institute of Health and Biomedical Innovation, QUT. The Queensland State Government, the Nicol Foundation and the Institute of Health and Biomedical Innovation had no further role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. JV is a Queensland Smart State Fellow.
- Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ: Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J Biol Chem. 2001, 276: 24232-24241. 10.1074/jbc.M010418200.View ArticlePubMed
- Moises HW, Yang L, Kristbjarnarson H, Wiese C, Byerley W, Macciardi F, Arolt V, Blackwood D, Liu X, Sjogren B, Aschauer HN, Hwu HG, Jang K, Livesley WJ, Kennedy JL, Zoega T, Ivarsson O, Bui MT, Yu MH, Havsteen B, Commenges D, Weissenbach J, Schwinger E, Gottesman II, Pakstis AJ, Wetterberg L, Kidd KK: An international two-stage genome-wide search for schizophrenia susceptibility genes. Nat Genet. 1995, 11: 321-324. 10.1038/ng1195-321.View ArticlePubMed
- Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, Harris-Kerr C, Wormley B, Sadek H, Kadambi B, Cesare AJ, Gibberman A, Wang X, O'Neill FA, Walsh D, Kendler KS: Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet. 2002, 71: 337-348. 10.1086/341750.PubMed CentralView ArticlePubMed
- Wang S, Sun CE, Walczak CA, Ziegle JS, Kipps BR, Goldin LR, Diehl SR: Evidence for a susceptibility locus for schizophrenia on chromosome 6pter-p22. Nat Genet. 1995, 10: 41-46. 10.1038/ng0595-41.View ArticlePubMed
- Duan J, Martinez M, Sanders AR, Hou C, Burrell GJ, Krasner AJ, Schwartz DB, Gejman PV: DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3' end of the gene. Hum Hered. 2007, 64: 97-106. 10.1159/000101961.PubMed CentralView ArticlePubMed
- Pae CU, Mandelli L, De Ronchi D, Kim JJ, Jun TY, Patkar AA, Serretti A: Dysbindin gene (DTNBP1) and schizophrenia in Korean population. Eur Arch Psychiatry Clin Neurosci. 2009, 259: 137-142. 10.1007/s00406-008-0830-y.View ArticlePubMed
- Konradi C, Heckers S: Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther. 2003, 97: 153-179. 10.1016/S0163-7258(02)00328-5.PubMed CentralView ArticlePubMed
- Moghaddam B: Bringing order to the glutamate chaos in schizophrenia. Neuron. 2003, 40: 881-884. 10.1016/S0896-6273(03)00757-8.View ArticlePubMed
- Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007, 13: 1102-1107. 10.1038/nm1632.View ArticlePubMed
- Bray NJ, Preece A, Williams NM, Moskvina V, Buckland PR, Owen MJ, O'Donovan MC: Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum Mol Genet. 2005, 14: 1947-1954. 10.1093/hmg/ddi199.View ArticlePubMed
- Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, Hahn CG, Siegel SJ, Trojanowski JQ, Gur RE, Blake DJ, Arnold SE: Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest. 2004, 113: 1353-1363.PubMed CentralView ArticlePubMed
- Weickert CS, Rothmond DA, Hyde TM, Kleinman JE, Straub RE: Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients. Schizophr Res. 2008, 98: 105-110. 10.1016/j.schres.2007.05.041.PubMed CentralView ArticlePubMed
- Weickert CS, Straub RE, McClintock BW, Matsumoto M, Hashimoto R, Hyde TM, Herman MM, Weinberger DR, Kleinman JE: Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry. 2004, 61: 544-555. 10.1001/archpsyc.61.6.544.View ArticlePubMed
- Tang J, LeGros RP, Louneva N, Yeh L, Cohen JW, Hahn CG, Blake DJ, Arnold SE, Talbot K: Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. Hum Mol Genet. 2009, 18: 3851-3863. 10.1093/hmg/ddp329.PubMed CentralView ArticlePubMed
- Raybould R, Green EK, MacGregor S, Gordon-Smith K, Heron J, Hyde S, Caesar S, Nikolov I, Williams N, Jones L, O'Donovan MC, Owen MJ, Jones I, Kirov G, Craddock N: Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1). Biol Psychiatry. 2005, 57: 696-701. 10.1016/j.biopsych.2005.01.018.View ArticlePubMed
- Snyder SH: Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am J Psychiatry. 1973, 130: 61-67.View ArticlePubMed
- Ujike H: Stimulant-induced psychosis and schizophrenia: the role of sensitization. Curr Psychiatry Rep. 2002, 4: 177-184. 10.1007/s11920-002-0024-7.View ArticlePubMed
- Kishimoto M, Ujike H, Motohashi Y, Tanaka Y, Okahisa Y, Kotaka T, Harano M, Inada T, Yamada M, Komiyama T, Hori T, Sekine Y, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S: The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biol Psychiatry. 2008, 63: 191-196. 10.1016/j.biopsych.2007.03.019.View ArticlePubMed
- Lawford BR, Young RM, Swagell CD, Barnes M, Burton SC, Ward WK, Heslop KR, Shadforth S, van Daal A, Morris CP: The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia. Schizophr Res. 2005, 73: 31-37. 10.1016/j.schres.2004.08.020.View ArticlePubMed
- Voisey J, Swagell CD, Hughes IP, Morris CP, van Daal A, Noble EP, Kann B, Heslop KA, Young RM, Lawford BR: The DRD2 gene 957C > T polymorphism is associated with posttraumatic stress disorder in war veterans. Depress Anxiety. 2009, 26: 28-33. 10.1002/da.20517.View ArticlePubMed
- Xu H, Kellendonk CB, Simpson EH, Keilp JG, Bruder GE, Polan HJ, Kandel ER, Gilliam TC: DRD2 C957T polymorphism interacts with the COMT Val158Met polymorphism in human working memory ability. Schizophr Res. 2007, 90: 104-107. 10.1016/j.schres.2006.10.001.View ArticlePubMed
- White MJ, Lawford BR, Morris CP, Young RM: Interaction between DRD2 C957T polymorphism and an acute psychosocial stressor on reward-related behavioral impulsivity. Behav Genet. 2009, 39: 285-295. 10.1007/s10519-008-9255-7.View ArticlePubMed
- Hill SY, Hoffman EK, Zezza N, Thalamuthu A, Weeks DE, Matthews AG, Mukhopadhyay I: Dopaminergic mutations: within-family association and linkage in multiplex alcohol dependence families. Am J Med Genet Part B. 2008, 147B: 517-526. 10.1002/ajmg.b.30630.PubMed CentralView ArticlePubMed
- Voisey J, Swagell CD, Hughes IP, Lawford BR, Young RM, Morris CP: Analysis of HapMap tag-SNPs in dysbindin (DTNBP1) reveals evidence of consistent association with schizophrenia. Eur Psychiatry. 2010, doi:10.1016/j.eurpsy.2009.11.011
- Achim AM, Maziade M, Raymond E, Olivier D, Merette C, Roy MA: How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull. 2009, doi:10.1093/schbul/sbp1148
- McCreadie RG: Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br J Psychiatry. 2002, 181: 321-325. 10.1192/bjp.181.4.321.View ArticlePubMed
- Keane TM, Caddell JM, Taylor KL: Mississippi Scale for Combat-Related Posttraumatic Stress Disorder: three studies in reliability and validity. J Consult Clin Psychol. 1988, 56: 85-90. 10.1037/0022-006X.56.1.85.View ArticlePubMed
- Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO: The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991, 86: 1119-1127. 10.1111/j.1360-0443.1991.tb01879.x.View ArticlePubMed
- Abramson JH: WINPEPI (PEPI-for-Windows): computer programs for epidemiologists. Epidemiol Perspect Innov. 2004, 1: 6-10.1186/1742-5573-1-6.PubMed CentralView ArticlePubMed
- Ott J: Utility programs for analysis of genetic linkage, Program, HWE version 1.10. 1988, New York: Columbia University
- Vilella E, Costas J, Sanjuan J, Guitart M, De Diego Y, Carracedo A, Martorell L, Valero J, Labad A, De Frutos R, Najera C, Molto MD, Toirac I, Guillamat R, Brunet A, Valles V, Perez L, Leon M, de Fonseca FR, Phillips C, Torres M: Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. J Psychiatr Res. 2008, 42: 278-288. 10.1016/j.jpsychires.2007.02.005.View ArticlePubMed
- Cox MM, Tucker AM, Tang J, Talbot K, Richer DC, Yeh L, Arnold SE: Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav. 2009, 8: 390-397. 10.1111/j.1601-183X.2009.00477.x.PubMed CentralView ArticlePubMed
- Kumamoto N, Matsuzaki S, Inoue K, Hattori T, Shimizu S, Hashimoto R, Yamatodani A, Katayama T, Tohyama M: Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributed to the down-regulation of dysbindin. Biochem Biophys Res Commun. 2006, 345: 904-909. 10.1016/j.bbrc.2006.04.163.View ArticlePubMed
- Iizuka Y, Sei Y, Weinberger DR, Straub RE: Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J Neurosci. 2007, 27: 12390-12395. 10.1523/JNEUROSCI.1689-07.2007.View ArticlePubMed
- Duan J, Sanders AR, Gejman PV: Genome-wide approaches to schizophrenia. Brain Res Bull. 2010, doi:10.1016/j.brainresbull.2010.04.009
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.